Session Details
[28-64-pm1]Modalities, biomolecules, biologics 1
Sat. Mar 28, 2026 1:10 PM - 3:10 PM JST
Sat. Mar 28, 2026 4:10 AM - 6:10 AM UTC
Sat. Mar 28, 2026 4:10 AM - 6:10 AM UTC
Room 64 (Collaboration Commons, RINPUKAN [1F]) (1)
Discusser: Akira Katsuyama, Yu Mikame
[28-64-pm1-01S]Mammalian cell display and functional evaluation of HER2-targeting BiTE antibodies
○Kotomi Hirai1, Taiki Abe1, Takumi Abe1, Tetsuya Kadonosono1 (1. School of Life Science and Technology,Institute of Science Tokyo)
[28-64-pm1-02S]Evaluation of cell adhesion activity of optimized integrin α4β1-binding peptides
○Reiya Atsumi1, Keisuke Hamada1, Yamato Kikkawa1, Yuji Yamada1 (1. Tokyo Univ. Pharm. Life Sci.)
[28-64-pm1-03]Mismatch-Selective Hybridization of Modified PNA Targeting KRAS G12D: Toward Precision Antisense Therapy
○Toshihiko Sakurai1, Azumi Naotaka2, Hamashita Yuusuke3 (1. Grad. Sch. of Systems Engineering, Kindai Univ., 2. Faculty of Engineering, Kindai Univ., 3. Grad. Sch.Sustainability Science, Tottori Uinv.)
[28-64-pm1-04S]Development of Liposomes Modified with uPAR-Targeting Helix-Loop-Helix Peptides for Drug Delivery
○Ryoichi Kira1, Yuto Nakatani2, Masataka Michigami1,2, Ikuhiko Nakase1,2, Ikuo Fujii1,2,3 (1. Grad. Sch. Sci., Osaka Metropolitan Univ., 2. Grad. Sch. Sci., Osaka Prefecture Univ., 3. Organization for Recearch Promotion, Osaka Metropolitan Univ.)
[28-64-pm1-05S]Inkjet printer-based technology for evaluating cell-selective drug delivery using CPP
○Sohei Ninomiya1, Mika Omura1, Yoshimasa Kawaguchi2, Daisuke Fujiwara1, Masataka Michigami1, Tomoka Takatani-Nakase3, Ikuo Fujii1,5, Shiroh Futaki4, Ikuhiko Nakase1 (1. Grad. Sch. Sci., Osaka Metropolitan Univ., 2. Inst. Chem. Res, 3. Dep. Pharm. Mukogawa Women's Univ., 4. Grad. Sch. Pharm. Sci., Kyoto Univ., 5. Organization for Recearch Promotion, Osaka Metropolitan Univ.)
[28-64-pm1-06S]Development of Light-Controlled Click Chemistry for Sequential Chemical Modification of Proteins
○Satoshi Fukuda1, Yamato Ezo2, Kenji Watanabe3, Takashi Niwa2,4, Takamitsu Hosoya4, Isao Kii1 (1. Grad. Sch. Med., Sci. & Tech., Shinshu Univ., 2. Grad. Sch. Pharm. Sci., Kyushu Univ., 3. Fac. Pharm. Sci., DWCLA, 4. LBB, IIR, Science Tokyo)
[28-64-pm1-07S]Evaluation of stability and translation efficiency of terminally hybridized mRNA-antisense oligonucleotide complexes
○Kota Iinuma1,2, Tahia Taufiq2,3, Hidekazu Hoshino2,3, Yuuya Kasahara2,3, Satoshi Obika1,2,4 (1. Sch. Pharm. Sci., UOsaka, 2. NIBN, 3. Grad. Sch. Pharm. Sci., UOsaka, 4. OTRI, UOsaka)
[28-64-pm1-08]Study on the Influence of Solid-Phase Support Treatment Conditions on Deamination Impurity Generation in Oligonucleotides
○Harei Sakurai1, Emi Saito1, Hirokazu Nankai1, Takao Inoue2, Junji Kawakami3, Satoshi Obika4 (1. GeneDesign, Inc. dba Ajinomoto Bio-pharma Services, 2. National Institute of Health Sciences, 3. FIRST, Konan University, 4. Graduate School of Pharmaceutical Sciences, Osaka University)
